AbbVie lost its CEO last year even as its most important drug experienced a patent cliff. However, the company's business remains robust thanks to a deep lineup and rich pipeline.

Reports Second-Quarter Diluted EPS of $0.77 on a GAAP Basis, a Decrease of 32.5 Percent; Adjusted Diluted EPS of $2.65, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $0....

Arguably, there's never a bad time to consider trustworthy dividend stocks. By securing passive income, you can complement any returns you generate through speculation.

These blue-chip companies have demonstrated strong dividend growth rates ranging from 7.69% to 15.8% annually over the past five years. The list includes diverse sectors such as retail, healthcare,...

We present a diversified yet simple portfolio of 6 stocks and one ETF with nearly 4% dividend yield. The portfolio has been designed for retirees and income investors whose needs are generally met ...

We recently sold our ABBV shares at $175. The stock has reached our target valuation at this price. More fundamentally, we think the market has corrected its overreaction to the Humira patent cliff...

AbbVie Inc. will announce its Q2 2024 earnings next Thursday, 25th July. The company has a new CEO, with insider Rob Michael taking the reins after long-term CEO Rick Gonzalez's retirement. Wall St...

At this writing, current inflation rate is 3% over the past 12 months. That's the reading as of the end of June.

AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq, giant cell arteritis.

Trump confirms he is "fine" after assassination attempt during rally in Pennsylvania, suspect dead. Global leaders condemn violence, wish Trump speedy recovery.

AbbVie is poised to keep a 52-year streak of dividend hikes going. Amgen offers more than a dividend with its promising pipeline.

Johnson & Johnson and AbbVie produce reliable earnings driven by sales of patent-protected drugs. Real estate investment trust Agree Realty makes monthly dividend payments.

Submissions are supported by the Phase 3 SELECT-GCA study demonstrating upadacitinib 15 mg with a 26-week steroid taper regimen achieved the primary endpoint of sustained remission from week 12 thr...

Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff- quite well and looks set to return to robust growth next year.

AbbVie on Wednesday lowered its 2024 adjusted profit forecast as the drugmaker expects to incur $937 million in acquisition-related expenses.